134 related articles for article (PubMed ID: 25192751)
1. Servier found to have breached industry code over disclosure of trial results.
Wise J
BMJ; 2014 Sep; 349():g5534. PubMed ID: 25192751
[No Abstract] [Full Text] [Related]
2. Sense About Science charity joins fight against bid to prevent transparency of trials.
Wise J
BMJ; 2015 Jun; 350():h3428. PubMed ID: 26109395
[No Abstract] [Full Text] [Related]
3. Drug trade bodies rally patient groups to deflect calls for full trial data.
O'Dowd A
BMJ; 2013 Jul; 347():f4702. PubMed ID: 23882001
[No Abstract] [Full Text] [Related]
4. Congress may force drug firms to reveal clinical trial data.
Check E
Nature; 2004 Sep; 431(7006):232. PubMed ID: 15371992
[No Abstract] [Full Text] [Related]
5. Roche medical director could face GMC if the company withheld relevant data on oseltamivir.
Kmietowicz Z
BMJ; 2012 Dec; 345():e8408. PubMed ID: 23233698
[No Abstract] [Full Text] [Related]
6. European ombudsman questions European Medicines Agency over AbbVie redactions.
Watson R
BMJ; 2014 Nov; 349():g6904. PubMed ID: 25406123
[No Abstract] [Full Text] [Related]
7. Investment managers back greater transparency of clinical trials.
Hawkes N
BMJ; 2015 Jul; 351():h4002. PubMed ID: 26207007
[No Abstract] [Full Text] [Related]
8. The whole truth: drug companies must tell us all they know about the medicines we take.
New Sci; 2004 May 1-7; 182(2445):3. PubMed ID: 15278970
[No Abstract] [Full Text] [Related]
9. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
10. Glaxo agrees to post results of drug trials on web site.
Harris G
N Y Times Web; 2004 Aug; ():C4. PubMed ID: 15540364
[No Abstract] [Full Text] [Related]
11. Drug giants fail to name compounds in trial database.
Wadman M
Nature; 2005 Jun; 435(7042):548. PubMed ID: 15931185
[No Abstract] [Full Text] [Related]
12. Out in the open.
Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130
[No Abstract] [Full Text] [Related]
13. Drug companies, doctors and disclosures.
Tuorto S; Chan MK; Adusumilli PS
Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772
[No Abstract] [Full Text] [Related]
14. Expose your clinical thinking.
Nat Biotechnol; 2004 Aug; 22(8):927. PubMed ID: 15286628
[No Abstract] [Full Text] [Related]
15. Drugmakers prefer silence on test data; firms violate US law by not registering trials.
Vedantam S
Washington Post; 2004 Jul; ():A1, A4. PubMed ID: 15290815
[No Abstract] [Full Text] [Related]
16. Drug-company data vaults to be opened.
Cressey D
Nature; 2013 Mar; 495(7442):419-20. PubMed ID: 23538802
[No Abstract] [Full Text] [Related]
17. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
18. Behind closed doors.
DeFrancesco L
Nat Biotechnol; 2014 Jun; 32(6):528-35. PubMed ID: 24911493
[No Abstract] [Full Text] [Related]
19. Best-kept secrets.
Nat Biotechnol; 2014 Jun; 32(6):499. PubMed ID: 24911473
[No Abstract] [Full Text] [Related]
20. Clinical trials transparency and the Trial and Experimental Studies Transparency (TEST) act.
Logvinov I
Contemp Clin Trials; 2014 Mar; 37(2):219-24. PubMed ID: 24440100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
